BMBenjamin Irving Meyer

Benjamin Irving Meyer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Benjamin Irving Meyer has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Beyond the Surface: A Systematic Review of Perforating and Penetrating Globe Injuries From Blepharoplasty

    by Benjamin I. Meyer, Marissa K. Shoji, Kambiz A. Zamani, Alison K. O.D. Bozung, Wendy W. Lee

    Purpose: This study aims to address the infrequent but serious complication of globe injuries in blepharoplasty. Methods: A case series of 3 patients with globe injuries postblepharoplasty is presented, along with a systematic literature review that revealed 13 previously reported cases. Quantitative and comparative analysis is described. Results: Injuries ranged from deep thermal burns to full-thickness corneal or scleral lacerations, with one instance of traumatic cataract. The median time from surgery to symptom onset was 1 day, with a concerning median delay of 7 days to presentation to an ophthalmologist. Visual outcomes were generally poor, with nearly all patients experiencing permanent visual morbidity. The systematic review revealed 3 cases of endophthalmitis following perforating scleral injuries. Comparative analysis showed no significant differences in visual outcomes between penetrating and perforating injuries. Conclusions: The findings of this study emphasize the need for increased vigilance for globe injuries that require prompt ophthalmological evaluation following blepharoplasty, especially considering the observed delay in presentation and the extent of visual morbidity. The study advocates for improved practitioner training in recognizing and managing these complications and underscores the importance of patient education regarding the potential risks and the necessity of timely postoperative care.


  • Bilateral Thermal Keratopathy Due to Plasma Skin Regeneration

    by Benjamin I. Meyer, Naomi E. Gutkind, Marissa K. Shoji, Andrew J. Rong

    A 40-year-old woman underwent periocular plasma skin regeneration, a cosmetic treatment for periorbital rejuvenation. She subsequently developed bilateral thermal keratitis, manifesting as blurred vision, irritation, and redness, with a vision decrease to 20/60 and 20/50 in her OD and OS, respectively. Examination demonstrated bilateral large, irregular corneal epithelial defects and edema, necessitating treatment with amniotic membrane grafts, bandage contact lenses, and hypertonic saline. One year posttreatment, her visual acuity improved to 20/20 and 20/25, albeit with ongoing symptomatic dryness and bilateral anterior stromal haze. This case, as only the second reported instance of ocular damage from periocular plasma skin regeneration, underscores the need for heightened awareness of potential ocular complications following plasma skin regeneration and reinforces the importance of protective measures during periocular procedures.


  • Open Access

    Defining the Reliability of Bladder Scan in Obese Patients with Postoperative Urinary Retention

    by Pranay Shah Ajay, Benjamin I Meyer, Monali Bs Shah, Adriana C Gamboa, Subir Goyal, Jeffrey M Switchenko, David A Kooby, Shishir K Md Maithel, Mihir M Md Shah

  • Acute Central Retinal Artery Occlusion Seen within 24 Hours at a Tertiary Institution

    by Wesley Chan, Alexis M. Flowers, Benjamin I. Meyer, Beau B. Bruce, Nancy J. Newman, Valérie Biousse


  • A Functional Non-coding RNA Is Produced from xbp-1 mRNA

    by Xiao Liu, Jean-Denis Beaudoin, Carrie Ann Davison, Sara G. Kosmaczewski, Benjamin I. Meyer, Antonio J. Giraldez, Marc Hammarlund


  • Conditional survival analysis of hepatocellular carcinoma

    by Mihir M. Shah, Benjamin I. Meyer, Kevin Rhee, Rachel E. NeMoyer, Yong Lin, Ching‐Wei D. Tzeng, Salma K. Jabbour, Timothy J. Kennedy, John L. Nosher, David A. Kooby, et al.

    Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer‐related mortality worldwide with an approximate 5‐year survival of greater than 50% in patients after surgical resection. Survival estimates have limited utility for patients who have survived several years after initial treatment. We analyzed how conditional survival (CS) after curative‐intent surgery for HCC predicts survival estimates over time.Methods: NCDB (2004‐2014) was queried for patients undergoing definitive surgical resection for HCC. Cumulative overall survival (OS) was calculated using the Kaplan‐Meier method, and CS at x years after diagnosis was calculated as CS1 = OS (X+5)/OS(X).Results: The final analysis encompassed 11 357 patients. Age, negative margin status, grade severity and radiation before surgery were statistically significant predictors of cumulative overall conditional survival (P ≤ .0001). Overall unconditional 5‐year survival was 65.7%, but CS estimates were higher. A patient who has already survived 3 years has an additional 2‐year, or 5‐year CS, estimate of 86.96%.Conclusion: Survival estimates following hepatic resection in HCC patients change according to survival time accrued since surgery. CS estimates are improved relative to unconditional OS. The impact of different variables influencing OS is likewise nonlinear over the course of time after surgery.


  • Optimal timing and treatment strategy for pancreatic cancer

    by Adriana C. Gamboa, Manali Rupji, Jeffrey M. Switchenko, Rachel M. Lee, Michael K. Turgeon, Benjamin I. Meyer, Maria C. Russell, Kenneth Cardona, David A. Kooby, Shishir K. Maithel, et al.

    Background: For pancreatic adenocarcinoma (PDAC), no studies have established any association between earlier treatment initiation and long‐term outcomes. In addition, an optimal type of initial treatment for the localized disease remains ill‐defined.Methods: Patients in the National Cancer Database (2004‐2015) with clinical stage I (CS‐I) and II (CS‐II) PDAC who underwent curative‐intent resection were included. Optimal time from diagnosis‐to‐treatment including neoadjuvant chemotherapy, neoadjuvant chemoradiation, or upfront surgery was assessed. An optimal type of treatment was evaluated. The primary outcome was overall survival (OS).Results: Among 29 167 patients, starting any treatment within 0 to 6 weeks was associated with improved median OS compared with 7 to 12 weeks (21.0 vs 20.1 months; P = .004). This persisted when accounting for sex, race, and Charlson‐Deyo score (hazard ratio [HR], 0.94; P = 0.02) and on subset analysis for CS‐I (23.5 vs 21.8 months; P = .04) and CS‐II (19.4 vs 18.3 months; P = .03). Neoadjuvant chemotherapy was associated with improved OS compared with neoadjuvant chemoradiation (25.6 vs 22.7 months; P < .0001) or US (25.6 vs 20.1 months; P < .0001) even when accounting for sex, race, and Charlson‐Deyo score (neoadjuvant chemoradiation: HR, 0.86; P < .001; US: HR, 0.79; P < .001). This improvement persisted in subset analysis with NC compared with neoadjuvant chemoradiation (CS‐I: 28.6 vs 25.0 months; CS‐II: 25.0 vs 22.9 months; both P < .0001) and to US (CS‐I: 28.6 vs 22.9 months; CS‐II: 24.7 vs 18.4 months; both P < .0001). On multivariable analysis for each CS‐I/CS‐II, NC remained associated with 20% improved survival compared with neoadjuvant chemoradiation or upfront surgery.Conclusions: For PDAC, initiation of therapy within 6 weeks from diagnosis is associated with improved survival, with neoadjuvant chemotherapy associated with the best survival compared with neoadjuvant chemoradiation or upfront surgery.


  • Should adenosquamous esophageal cancer be treated like adenocarcinoma or squamous cell carcinoma?

    by Adriana C. Gamboa, Benjamin I. Meyer, Jeffrey M. Switchenko, Manali Rupji, Rachel M. Lee, Michael K. Turgeon, Maria C. Russell, Kenneth Cardona, David A. Kooby, Shishir K. Maithel, et al.

    Background Esophageal adenocarcinoma (AC) and squamous cell carcinoma (SCC) have distinct outcomes, treatment strategies, and response profiles to therapy. Adenosquamous carcinoma (ASC) is thought to behave more aggressively than each of its counterparts. The aim of this study is to determine if ASC is best managed as AC or SCC. Methods National Cancer Database (2004‐2015) was queried for patients with nonmetastatic esophageal ASC. The analysis was stratified by clinical node‐negative (cN0) or clinical node‐positive (cN1‐3). Treatment was categorized into chemoradiation alone, surgery alone, or preoperative chemoradiation followed by surgery. The primary outcome was 5‐year overall survival (OS). Results Among 352 patients, 43% were cN0 (n = 151), 57% were cN1‐3 (n = 201) and 55% had chemoradiation alone (n = 194), 15% surgery alone (n = 53), and 30% preoperative chemoradiation (n = 105). Among patients who had preoperative chemoradiation, 20% had pathologic complete response (n = 17). For either cN0 or cN1‐3, Charlson‐Deyo Comorbidity Index did not differ among the treatment groups (all p > 0.05). On Kaplan‐Meier analysis for cN0, treatment with surgery alone had comparable OS to preoperative chemoradiation (47% vs 34%; P = .5) and each had improved OS compared to chemoradiation alone (30%; P = .02; P = .06). On univariate analysis for cN0, clinical T category was not associated with OS. For cN1‐3, however, preoperative chemoradiation was associated with improved OS when compared to chemoradiation alone or surgery alone (27% vs 19% vs 0%; P < .001). This persisted when accounting for age and clinical T category (hazard ratio: 0.45; P < .001). Conclusion Esophageal ASC behaves more like AC in response to chemoradiation and survival based on treatment modality. A complete response to chemoradiation is only 20% unlike what has been shown for SCC, where chemoradiation is an acceptable definitive therapy. Esophageal ASC should be managed more like AC.


  • RNA ligation in neurons by RtcB inhibits axon regeneration

    by Sara Guckian Kosmaczewski, Sung Min Han, Bingjie Han, Benjamin Irving Meyer, Huma S. Baig, Wardah Athar, Alexander T. Lin-Moore, Michael R. Koelle, Marc Hammarlund

    Significance: Neurons use RNA modification to control specific functions by generating increased complexity and dynamism relative to the static genome. Known mechanisms of neuronal RNA modification include neuron-specific regulation of alternative splicing and mRNA editing by adenosine deaminases. Here, we identify a previously unidentified mechanism for RNA modification in neurons that is mediated by the RNA ligase RtcB. RtcB activity acts in neurons to regulate axon regeneration, and this neuronal function is independent of RtcB’s previously identified roles in tRNA and XBP1 mRNA ligation. RtcB’s function in axon regeneration is also independent of its cofactor archease, and RtcB translocates from the cell body of neurons to the stumps of injured axons. Taken together, these data establish a new function and mechanism for RtcB in inhibiting axon regeneration.


  • The RtcB RNA ligase is an essential component of the metazoan unfolded protein response

    by Sara Guckian Kosmaczewski, Tyson James Edwards, Sung Min Han, Matthew J Eckwahl, Benjamin Isaiah Meyer, Sally Peach, Jay R Hesselberth, Sandra L Wolin, Marc Hammarlund

    RNA ligation can regulate RNA function by altering RNA sequence, structure and coding potential. For example, the function of XBP1 in mediating the unfolded protein response requires RNA ligation, as does the maturation of some tRNAs. Here, we describe a novel in vivo model in Caenorhabditis elegans for the conserved RNA ligase RtcB and show that RtcB ligates the xbp‐1 mRNA during the IRE‐1 branch of the unfolded protein response. Without RtcB, protein stress results in the accumulation of unligated xbp‐1 mRNA fragments , defects in the unfolded protein response, and decreased lifespan. RtcB also ligates endogenous pre‐tRNA halves, and RtcB mutants have defects in growth and lifespan that can be bypassed by expression of pre‐spliced tRNAs. In addition, animals that lack RtcB have defects that are independent of tRNA maturation and the unfolded protein response. Thus, RNA ligation by RtcB is required for the function of multiple endogenous target RNAs including both xbp‐1 and tRNAs. RtcB is uniquely capable of performing these ligation functions, and RNA ligation by RtcB mediates multiple essential processes in vivo . ![][1] Work in C. elegans shows that RtcB is the RNA ligase for xbp‐1 splicing in the IRE‐1 branch of the UPR. RtcB also ligates endogenous tRNA substrates and promotes lifespan and development. [1]: pending:yes